Aim In this study we evaluated the effects of Riamilovir on SARS-CoV-2 viral shedding and on admission duration in patients with moderate COVID-19 Materials and methods We have used data from 69 health records of patients with moderate severe PCR confirmed SARS-CoV-2 infection Control group included 34 patients treated with off-label riamilovir 1250 mg per day for 5 days (250 mg 5 times a day), comparison groups - 35 patients, who received ribavirin and umifenovir 800 mg a day for 5 days The antiviral therapy was administered within 72 hours from the onset of the disease The primary endpoints were elimination of virus in oropharyngeal and nasopharyngeal swabs on 7 day of admission and discharge from the hospital by 14 day Results Patients assigned to riamilovir had significantly shorter time to clinical improvement as well as increased PCR negative rate by day 7 Conclusion Yearly administration of riamilovir as opposed to the umifenovir and ribavirin in therapy of moderate SARS-CoV-2 infection was associated with significant shorter time to clinical improvement by 14 day of hospitalization PCR negative rate by 7 days of hospitalization is significantly more likely in riamilovir group © 2021 Consilium Medikum All rights reserved
Evaluation of the effectiveness of Riamilovir in the complex therapy of patients with COVID-19